Topics

Ligand Completes Enrollment of Phase 1 Clinical Trial of Captisol-enabled Iohexol

09:00 EDT 2 May 2019 | Businesswire
This article has expired, however you can still download the PDF.
Preview:
Top-line data expected Q3 of 2019 Also reports recent results from clinician survey on radiocontrast agent selection and use Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces completion o...

Other Sources for this Article

Ligand Pharmaceuticals Incorporated
Todd Pettingill
investors@ligand.com
(858) 550-7893
@Ligand_LGND

LHA
Bruce Voss
bvoss@lhai.com
(310) 691-7100

NEXT ARTICLE

More From BioPortfolio on "Ligand Completes Enrollment of Phase 1 Clinical Trial of Captisol-enabled Iohexol"

Quick Search

Relevant Topics

BioPortfolio - life science, medical devices and pharmaceutical conference
BioPortfolio is a leading news, information and knowledge resource covering the global life science industries impacted on by biotechnology. The site aims to provide the lay person, the researcher and the management executive with a single location to so...

Clincial Trials
In a clinical trial or interventional study, participants receive specific interventions according to the research plan or protocol created by the investigators. These interventions may be medical products, such as drugs or devices; procedures; or change...

Nephrology - kidney function
Nephrology is a specialty of medicine and pediatrics that concerns itself with the study of normal kidney function, kidney problems, the treatment of kidney problems and renal replacement therapy (dialysis and kidney transplantation). Systemic conditions...